Safety: Hematologic and Renal Function Before and 6–8 Weeks After 177Lu-FAP-2286 PTRT According to Common Terminology Criteria for Adverse Events, Version 5.0
| Hemoglobin (mmol/L) | Leukocyte count (billion cells/L) | Thrombocyte count (billion cells/L) | eGFR (mL/min/1.73 m2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade | Before therapy (n = 11) | After first PTRT (n = 11) | After second PTRT (n = 8) | Before therapy (n = 11) | After first PTRT (n = 11) | After second PTRT (n = 8) | Before therapy (n = 11) | After first PTRT (n = 11) | After second PTRT (n = 8) | Before therapy (n = 11) | After first PTRT (n = 11) | After second PTRT (n = 8) |
| 1 | 4 | 5 | 3 | 2 | 1 | 0 | 5 | 3 | 5 | 0 | 0 | 0 |
| 2 | 2 | 3 | 4 | 2 | 2 | 2 | 0 | 0 | 0 | 1 | 1* | 1* |
| 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | NA | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 |
*There was additional non-G3 acute (on preexisting chronic G2) prerenal renal insufficiency after both first and second cycles, which was reversible.
eGFR = estimated glomerular filtration rate; NA = not applicable before 177Lu-FAP-2286 PTRT (grade 5 represents death).